Bank of Montreal Can Makes New Investment in scPharmaceuticals Inc. (NASDAQ:SCPH)

Bank of Montreal Can bought a new stake in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 351,806 shares of the company's stock, valued at approximately $1,544,000. Bank of Montreal Can owned approximately 0.98% of scPharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in SCPH. AIGH Capital Management LLC boosted its position in scPharmaceuticals by 3.4% in the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company's stock valued at $15,244,000 after buying an additional 115,206 shares in the last quarter. Rubric Capital Management LP raised its position in scPharmaceuticals by 29.0% in the 4th quarter. Rubric Capital Management LP now owns 3,500,000 shares of the company's stock valued at $21,945,000 after purchasing an additional 786,713 shares during the last quarter. King Luther Capital Management Corp boosted its stake in scPharmaceuticals by 51.8% in the second quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company's stock worth $9,592,000 after purchasing an additional 752,005 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in shares of scPharmaceuticals by 76.9% during the second quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company's stock worth $2,163,000 after purchasing an additional 216,122 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of scPharmaceuticals by 15.1% in the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company's stock valued at $375,000 after buying an additional 11,269 shares in the last quarter. Institutional investors own 89.52% of the company's stock.

scPharmaceuticals Trading Down 1.4 %

SCPH traded down $0.06 during mid-day trading on Friday, reaching $4.28. The stock had a trading volume of 200,745 shares, compared to its average volume of 314,153. The firm's fifty day simple moving average is $4.90 and its two-hundred day simple moving average is $4.62. The stock has a market capitalization of $214.13 million, a P/E ratio of -2.89 and a beta of 0.13. scPharmaceuticals Inc. has a 52 week low of $3.24 and a 52 week high of $6.77. The company has a debt-to-equity ratio of 4.32, a quick ratio of 3.66 and a current ratio of 4.84.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The firm had revenue of $8.05 million during the quarter, compared to analyst estimates of $8.04 million. scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. On average, equities analysts predict that scPharmaceuticals Inc. will post -1.34 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Monday, August 19th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.